Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Yu

Showing results (91-100 of 91) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 91 results.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 10

Showing results (91-100 of 91) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 91 results.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 10